Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Century Therapeutics ( (IPSC) ) is now available.
On February 26, 2025, Century Therapeutics received a deficiency letter from Nasdaq due to non-compliance with the $1.00 minimum bid price requirement. Despite failing to meet the initial compliance deadline of August 26, 2025, Nasdaq granted an extension until February 23, 2026, and approved the company’s transfer to The Nasdaq Capital Market. Century Therapeutics plans to monitor its stock price and consider a reverse stock split to regain compliance, although there is no assurance of success.
The most recent analyst rating on (IPSC) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
Spark’s Take on IPSC Stock
According to Spark, TipRanks’ AI Analyst, IPSC is a Underperform.
Century Therapeutics faces significant challenges with ongoing operational losses and negative cash flow, despite strong revenue growth and a solid balance sheet. The recent workforce reduction highlights financial strain. Technical indicators suggest bearish momentum, and the negative P/E ratio reflects the company’s unprofitability.
To see Spark’s full report on IPSC stock, click here.
More about Century Therapeutics
Century Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment.
Average Trading Volume: 980,520
Technical Sentiment Signal: Sell
Current Market Cap: $43.2M
See more data about IPSC stock on TipRanks’ Stock Analysis page.